Back to Search
Start Over
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
- Source :
-
Hypertension (Dallas, Tex. : 1979) [Hypertension] 2014 Oct; Vol. 64 (4), pp. 731-7. Date of Electronic Publication: 2014 Jun 30. - Publication Year :
- 2014
-
Abstract
- Glucagon-like peptide-1 receptor agonists, used to treat type 2 diabetes mellitus, are associated with small reductions in systolic blood pressure (SBP) and increases in heart rate. However, findings based on clinic measurements do not adequately assess a drug's 24-hour pharmacodynamic profile. The effects of dulaglutide, a once-weekly glucagon-like peptide-1 receptor agonist, on BP and heart rate were investigated using ambulatory BP monitoring. Patients (n=755; 56±10 years; 81% white; 48% women), with type 2 diabetes mellitus, taking ≥1 oral antihyperglycemic medication, with a clinic BP between 90/60 and 140/90 mm Hg were randomized to dulaglutide (1.5 or 0.75 mg) or placebo subcutaneously for 26 weeks. Ambulatory BP monitoring was performed at baseline and at 4, 16, and 26 weeks. The primary end point was change from baseline to week 16 in mean 24-hour SBP, a tree gatekeeping strategy compared the effects of dulaglutide to placebo. Both doses of dulaglutide were noninferior to placebo for changes in 24-hour SBP and diastolic blood pressure, and dulaglutide 1.5 mg significantly reduced SBP (least squares mean difference [95% confidence interval]), -2.8 mm Hg [-4.6, -1.0]; P≤0.001). Dulaglutide 0.75 mg was noninferior to placebo (1.6 bpm; [0.3, 2.9]; P≤0.02) for 24-hour heart rate (least squares mean difference [95% confidence interval]), but dulaglutide 1.5 mg was not (2.8 bpm [1.5, 4.2]). Dulaglutide 1.5 mg was associated with a reduction in 24-hour SBP and an increase in 24-hour heart rate. The mechanisms responsible for the observed effects remain to be clarified.<br /> (© 2014 American Heart Association, Inc.)
- Subjects :
- Aged
Blood Pressure physiology
Blood Pressure Monitoring, Ambulatory
Diabetes Mellitus, Type 2 blood
Diabetes Mellitus, Type 2 physiopathology
Diarrhea chemically induced
Double-Blind Method
Drug Administration Schedule
Female
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptides adverse effects
Glucagon-Like Peptides therapeutic use
Glycated Hemoglobin metabolism
Heart Rate physiology
Humans
Hypoglycemic Agents adverse effects
Hypoglycemic Agents therapeutic use
Immunoglobulin Fc Fragments adverse effects
Injections, Subcutaneous
Male
Middle Aged
Nausea chemically induced
Recombinant Fusion Proteins adverse effects
Treatment Outcome
Vomiting chemically induced
Blood Pressure drug effects
Diabetes Mellitus, Type 2 drug therapy
Glucagon-Like Peptides analogs & derivatives
Heart Rate drug effects
Immunoglobulin Fc Fragments therapeutic use
Receptors, Glucagon agonists
Recombinant Fusion Proteins therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4563
- Volume :
- 64
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Hypertension (Dallas, Tex. : 1979)
- Publication Type :
- Academic Journal
- Accession number :
- 24980665
- Full Text :
- https://doi.org/10.1161/HYPERTENSIONAHA.114.03062